Enumerate five differences between benign and malignant tumours. Describe the mechanisms by which the tumour cells evade the immune system.
10 marks · directive: Enumerate; Describe
The core of a good answer
Benign tumours are mostly well differentiated, grow slowly within a fibrous capsule, do not invade or metastasise and usually do not return after removal, while malignant tumours are often undifferentiated, faster growing, invasive and metastatic; tumour cells evade immunity by lowering MHC class I or through defects in antigen processing (TAP, tapasin), by immunoediting that selects less immunogenic clones, by producing PD-L1, and by creating a suppressive environment with regulatory T cells, myeloid-derived suppressor cells and cytokines such as TGF-beta and IL-10.
An outline written by upsc.help, not an official UPSC answer; every fact checked by a separate review. How we work
What the question asks
Five marks: a table of five or more differences. Five marks: the immune evasion mechanisms, organised as hiding from recognition and actively suppressing the response, with the therapeutic relevance of checkpoint inhibitors.
Answer outline
Introduction
A benign tumour is a mass of cells that does not invade neighbouring tissue or metastasise and is typically made of cells that strongly resemble a normal cell type; malignant tumours are invasive or metastatic.
Differences between benign and malignant tumours
- Differentiation: benign mostly well differentiated; malignant often undifferentiated (with exceptions both ways).
- Rate of growth: benign usually slower than malignant.
- Capsule and local invasion: benign grows in a contained area, usually within a fibrous connective tissue capsule, and is non-invasive; malignant is invasive.
- Metastasis: absent in benign; malignant tumours are invasive or metastatic, though some such as basal cell carcinoma are mostly non-metastatic.
- Recurrence: benign tumours usually do not return when removed; recurrence may indicate malignant transformation.
- Nomenclature: benign take the suffix -oma (adenoma, lipoma); -carcinoma, -sarcoma and -blastoma generally denote cancers; melanoma and seminoma are malignant despite their names.
- Effect on host: benign tumours act by mass effect or by hormone overproduction (thyroid and adrenocortical adenomas), and benign brain tumours can be life-threatening because of their location.
Mechanisms of immune evasion
- Immunoediting: elimination, equilibrium and escape; tumour clones less responsive to the immune system gain dominance over time.
- Some cancer cells lower MHC class I expression and avoid cytotoxic T cells; defects in the transporter associated with antigen processing (TAP) or tapasin reduce antigen presentation.
- Immune checkpoints: tumour cells can produce PD-L1, which acts on PD-1 on T cells; CTLA-4, upregulated on activated T cells, binds CD80/86 and dampens the response.
- Suppressive environment: TGF-beta drives CD4+ T cells to become regulatory T cells, which form an immunosuppressive microenvironment; myeloid-derived suppressor cells produce TGF-beta and IL-10 and suppress T cells, dendritic cells and macrophages; tumour-associated macrophages promote angiogenesis.
Therapeutic relevance
- Checkpoint inhibitors: ipilimumab blocks CTLA-4 and nivolumab blocks PD-1, increasing the anti-tumour T cell response.
Conclusion
Malignancy is defined by invasion and metastasis, and a cancer must also escape the immune system to survive; checkpoint inhibitors aim to reverse that escape.
Examples and data to cite
- Ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) are approved cancer drugs.
Facts to remember
- Benign tumours are usually encapsulated in fibrous connective tissue and non-invasive.
- Benign brain tumours can be life-threatening because of their location.
- Cancer immunoediting has three phases: elimination, equilibrium and escape.
- PD-L1 can be produced by tumour cells and acts on PD-1 to dampen T cell responses.